1.27
+0.05(+4.10%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.22 |
| Day High | 1.31 |
| Day Low | 1.2 |
| 52-Week High | 3.86 |
| 52-Week Low | 1.19 |
| Volume | 90,685 |
| Average Volume | 2.3M |
| Market Cap | 5.4M |
| PE | -0.48 |
| EPS | -2.63 |
| Moving Average 50 Days | 1.55 |
| Moving Average 200 Days | 2.08 |
| Change | 0.05 |
If you invested $1000 in STRATA Skin Sciences, Inc. (SSKN) 10 years ago, it would be worth $22.68 as of December 25, 2025 at a share price of $1.27. Whereas If you bought $1000 worth of STRATA Skin Sciences, Inc. (SSKN) shares 5 years ago, it would be worth $80.89 as of December 25, 2025 at a share price of $1.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
GlobeNewswire Inc.
Dec 09, 2025 1:15 PM GMT
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) Nove
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansionHORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of d